Celebrating the Winners of the OBN Awards 2025
OBN (UK) Ltd is thrilled to announce the winners of the 17th annual OBN Awards, an evening organised by OBN that celebrates innovation and outstanding achievement across the life sciences industry.
Full details below:
The Best Start-Up Biotech Company Award, sponsored by Milton Park, was awarded to Draig Therapeutics, a clinical-stage neuropsychiatry company dedicated to delivering next-generation treatments for neuropsychiatric disorders.
The Best Early Stage Medtech Company Award, sponsored by Penningtons Manches Cooper was collected by Novai, whose mission is to combat blindness by pioneering cellular level disease detection using its DARC biomarker technology.
BDO presented the Most Transformative Healthtech Company Award to Neuronostics who have developed a software as a medical device that supports clinical decision making in neurology.
The judges awarded the BioSeed ‘One to Watch’ Award, presented by Syneos Health to Serenatis Bio, a biotech developing three novel drugs to treat obsessive-compulsive disorder (OCD), a common yet poorly treated and devastating mental illness.
Presented by Ipsen, the Emerging Life Sciences Entrepreneur of the Year Award went to Suzanne Eldridge, co-Founder & Director of ReFleks, a spin-out company from Queen Mary University of London.
The Most Impactful Industry Collaboration Award, sponsored by Mills & Reeve, was presented to The Milner Therapeutics Institute, a research institute at the University of Cambridge, with an overarching vision to convert pioneering science into therapies by driving academic-industry partnerships.
Sponsored by Thermo Fisher Scientific, the Best Emerging Biotech Company Award went to AviadoBio, who are working to translate groundbreaking science and precision delivery into life-changing gene therapies for people living with neurological conditions.
The Best Established Biotech Company Award, sponsored by Precision for Medicine, went to Exonate, a therapeutic company with a phase II ready clinical stage asset for the treatment of Non Proliferative Diabetic Retinopathy.
The final Award of the evening, the Special Recognition Award, was presented by OBN chairman Paul Edwards, to Prof Christopher Shaw, a globally recognised neurologist, neurogeneticist, and a pioneer in neurodegenerative disease research. He has dedicated most of his career to this research field, driven huge progress in it, influenced clinical process, and later in his career, translated his academic work into a flourishing, clinical-stage spinout – showing that it’s never too late to translate!
